Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KETOHCA trial: ketamine sedation as neuroprotective agent following out-of-hospital cardiac arrest
2024-515987-29-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in cardiac arrest (SCA) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Neuron-specific enolase (NSE) at 48 hours. Planned start Oct 2024; status: authorised.
02
Drugs
esketamine
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on 2024-515987-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515987-29-00.